drugset

drugset / Trial / NCT03668340

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

NCT03668340 ↗

Phase 2 Active not recruiting 49 enrolled Dana-Farber Cancer Institute AstraZeneca · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying an investigational drug as a possible treatment for uterine cancer. The drug involved in this study is: -AZD1775

Timeline

Start: 2018-10-22
Primary completion: 2026-07-01
Completion: 2027-07-01

Publications

Liu JF, Xiong N, Campos SM, Wright AA, Krasner C, Schumer S, Horowitz N, Veneris J, Tayob N, Morrissey S, West G, Quinn R, Matulonis UA, Konstantinopoulos PA. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 May 10;39(14):1531-1539. doi: 10.1200/JCO.20.03167. Epub 2021 Mar 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adavosertib	Small molecule	300 mg	Oral

Indications